<div id="readability-page-1"><p><span>Baxter International (NYSE:BAX - Get Free Report)</span> had its target price reduced by equities researchers at Wells Fargo &amp; Company  from $21.00 to $19.00 in a research report issued to clients and investors on Friday,MarketScreener reports. The brokerage presently has an &#34;equal weight&#34; rating on the medical instruments supplier's stock. Wells Fargo &amp; Company's price objective indicates a potential downside of 0.37% from the stock's previous close.</p><ul><li>The Value Deepens for Medtech Stocks: Reversal Imminent</li></ul><p>Several other brokerages have also issued reports on BAX. Stifel Nicolaus reduced their target price on shares of Baxter International from $25.00 to $22.00 in a research note on Friday, October 31st. Jefferies Financial Group decreased their target price on Baxter International from $25.00 to $21.00 and set a &#34;hold&#34; rating for the company in a research note on Thursday, October 30th. Argus cut Baxter International from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Friday, October 31st. JPMorgan Chase &amp; Co. cut their price objective on shares of Baxter International from $25.00 to $19.00 in a research report on Friday, October 31st. Finally, Cowen  reiterated a &#34;hold&#34; rating on shares of Baxter International in a report on Thursday, October 30th. Two equities research analysts have rated the stock with a Buy rating, ten have assigned  a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $22.00.</p><div><p><span></span><span>Get <strong>Baxter International</strong> alerts:</span></p></div><p><b>Get Our Latest Stock Report on BAX</b></p><h2>Baxter International Trading Up 0.9%</h2><ul><li>A Significant Reversal is in Sight for These 5 Med Tech Companies</li></ul><p>Shares of BAX opened at $19.07 on Friday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 1.18 and a current ratio of 1.84. The company has a market cap of $9.80 billion, a price-to-earnings ratio of -28.79, a PEG ratio of 1.05 and a beta of 0.61. The stock has a fifty day moving average price of $20.07 and a two-hundred day moving average price of $24.45. Baxter International has a 52-week low of $17.40 and a 52-week high of $37.74. </p><p>Baxter International (NYSE:BAX - Get Free Report) last issued its quarterly earnings data on Thursday, October 30th. The medical instruments supplier reported $0.69 EPS for the quarter, topping analysts' consensus estimates of $0.60 by $0.09. The firm had revenue of $2.84 billion for the quarter, compared to analyst estimates of $2.88 billion. Baxter International had a negative net margin of 3.09% and a positive return on equity of 17.38%. The company's revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.80 EPS. Baxter International has set its Q4 2025 guidance at 0.520-0.570 EPS and its FY 2025 guidance at 2.350-2.400 EPS.  Analysts predict that  Baxter International will post 2.48 EPS for the current fiscal year. </p><h2>Institutional Trading of Baxter International</h2><ul><li>5 Good Reasons it's Time to Buy High-Yield Dividend King 3M</li></ul><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in BAX. Horizon Investments LLC grew its position in shares of  Baxter International by 5.0% in the 1st quarter. Horizon Investments LLC now owns 7,438 shares of the medical instruments supplier's stock valued at $255,000 after acquiring an additional 351 shares during the period.  BI Asset Management Fondsmaeglerselskab A S lifted its stake in  Baxter International by 41.7% in the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 20,063 shares of the medical instruments supplier's stock valued at $687,000 after purchasing an additional 5,907 shares during the last quarter.  Ameriprise Financial Inc. grew its holdings in  Baxter International by 1.1% during the first quarter. Ameriprise Financial Inc. now owns 7,540,942 shares of the medical instruments supplier's stock worth $258,140,000 after purchasing an additional 83,973 shares during the period.  Allstate Corp increased its position in  Baxter International by 10.5% during the first quarter. Allstate Corp now owns 17,041 shares of the medical instruments supplier's stock worth $583,000 after buying an additional 1,621 shares during the last quarter.  Finally, SVB Wealth LLC bought a new stake in  Baxter International in the first quarter valued at approximately $138,000. 90.19% of the stock is owned by institutional investors. </p><h2>Baxter International Company Profile</h2> (Get Free Report)<p>Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.</p><h2>See Also</h2><ul><li>Five stocks we like better than Baxter International</li><li>Biggest Stock Losers - Today’s Biggest Percentage Decliners</li><li>Santa Claus May Be Coming Early for Palantir Investors</li><li>3 Tickers Leading a Meme Stock Revival</li><li>4 Canadian Oil Stocks That Are Filling the Heavy Crude Gap</li><li>What is the Dogs of the Dow Strategy? Overview and Examples</li><li>Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJBWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJBWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Baxter International Right Now?</h2><p>Before you consider Baxter International, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Baxter International wasn't on the list.</p><p>While Baxter International currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Wells Fargo & Company has lowered its price target for Baxter International from $21.00 to $19.00, maintaining an "equal weight" rating. Other brokerages have also reduced their target prices, with a consensus rating of "Hold" and a target price of $22.00. Baxter International's stock opened at $19.07, with a market cap of $9.80 billion. The company reported better-than-expected quarterly earnings, with a revenue increase of 5% year-over-year.</p>

Wells Fargo & Company Issues Pessimistic Forecast for Baxter International (NYSE:BAX) Stock Price